Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
et1402l1-artemis t cells
- Development stage
- Phase 1
- Lead developer
- Eureka Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
ET1402L1-ARTEMIS T cells is an autologous chimeric antigen receptor (CAR) T cell therapy developed to target alpha-fetoprotein (AFP), a tumor-associated antigen overexpressed in liver cancers such as hepatocellular carcinoma and hepatoblastoma. The therapy involves collecting a patient's own T cells, genetically engineering them to express a proprietary ARTEMIS® cell receptor that incorporates a human antibody targeting the AFP-peptide/HLA-A2 complex, and reinfusing these modified cells back into the patient. This approach enables selective recognition and killing of AFP-positive cancer cells via immunologic cytotoxicity and natural TCR-signaling pathways, with additional co-stimulation for enhanced activity. The drug is being developed primarily by Eureka Therapeutics in collaboration with academic partners for pediatric and adult liver cancers, including relapsed/refractory hepatoblastoma and hepatocellular carcinoma[1][3][4][5][6].
- Brand names
- ARTEMIS
- Other names
- ARTEMIS T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on et1402l1-artemis t cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on et1402l1-artemis t cells.